Abstract

Primary aldosteronism (PA) is the most common cause of secondary hypertension. The paucity of good animal models hinders our understanding of the pathophysiology of PA and the hypertensive mechanism of PA remains incompletely known. It was recently reported that genetic deletion of TWIK-related acid-sensitive potassium-1 and potassium-3 channels from mice (TASK−/−) generates aldosterone excess and mild hypertension. We addressed the hypertensive mechanism by assessing autonomic regulation of cardiovascular activity in this TASK−/− mouse line that exhibits the hallmarks of PA. Here, we demonstrate that TASK−/− mice were hypertensive with 24-h ambulatory arterial pressure. Either systemic or central blockade of the mineralocorticoid receptor (MR) markedly reduced elevated arterial pressure to normal level in TASK−/− mice. The response of heart rate to the muscarinic cholinergic receptor blocker atropine was similar between TASK−/− and wild-type mice. However, the responses of heart rate to the β-adrenergic receptor blocker propranolol and of arterial pressure to the ganglion blocker hexamethonium were enhanced in TASK−/− mice relative to the counterparts. Moreover, the bradycardiac rather than tachycardiac gain of the arterial baroreflex was significantly attenuated and blockade of MRs to a large degree rescued the dysautonomia and baroreflex gain in TASK−/− mice. Overall, the present study suggests that the MR-dependent dysautonomia and reduced baroreflex gain contribute to the development of hyperaldosteronism-related hypertension.

Highlights

  • Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, accounting for ~10% of hypertensive patients and ~20% of resistant hypertension (Douma et al, 2008)

  • We demonstrate hyperaldosteronism-related and MRdependent hypertension in a TASK−/− mouse line that represents a PA model

  • These findings consolidate the understanding of the mechanism underlying hyperaldosteronism-associated hypertension

Read more

Summary

Introduction

Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, accounting for ~10% of hypertensive patients and ~20% of resistant hypertension (Douma et al, 2008). Intracerebroventricular (ICV) infusions of Aldo/DOC at doses that were ineffective when infused systemically were found to raise arterial pressure, and this central pressor effect was blocked by ICV infusion of MR antagonists (Gomez-Sanchez, 1986; Gomez-Sanchez and Gomez-Sanchez, 2012). Both acute and chronic administration of Aldo impaired baroreflex in animals (Wang, 1994) and healthy humans (Heindl et al, 2006; Monahan et al, 2007). These mechanisms are insufficient to elucidate the onset and development of hyperaldosteronism-related hypertension

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.